{"id":862646,"date":"2025-06-23T10:17:35","date_gmt":"2025-06-23T14:17:35","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/neuroone-patient-surpasses-one-year-milestone-of-seizure-freedom-following-treatment-with-onerf-ablation-system\/"},"modified":"2025-06-23T10:17:35","modified_gmt":"2025-06-23T14:17:35","slug":"neuroone-patient-surpasses-one-year-milestone-of-seizure-freedom-following-treatment-with-onerf-ablation-system","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/neuroone-patient-surpasses-one-year-milestone-of-seizure-freedom-following-treatment-with-onerf-ablation-system\/","title":{"rendered":"NeuroOne\u00ae Patient Surpasses One Year Milestone of Seizure Freedom Following Treatment with OneRF\u00ae Ablation System"},"content":{"rendered":"
\n

\n Patient Treated with OneRF<\/em>
\n
\n \u00ae<\/em>
\n <\/sup>
\n Ablation System Previously Experienced up to 10 Seizures a Day<\/em>\n <\/p>\n

\n EDEN PRAIRIE, Minn., June 23, 2025 (GLOBE NEWSWIRE) — <\/strong>NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced that Clara\u2014an early patient treated with the Company\u2019s patented OneRF\u00ae<\/sup> Ablation System\u2014has successfully surpassed the one year milestone of being seizure free.<\/p>\n

Clara was one of the first patients to undergo treatment using NeuroOne\u2019s OneRF\u00ae<\/sup> platform. Since the procedure in June 2024, Clara has been completely seizure-free, which has greatly improved her quality of life.<\/p>\n

Videos of Clara\u2019s journey can be found on the company\u2019s website<\/a>, as well as features on Fox News<\/a> and Good Morning America<\/a>.<\/p>\n

The OneRF\u00ae<\/sup> Ablation System is the first and only FDA 510(k)-cleared device that uses the same sEEG electrode for both diagnostic and therapeutic applications. It not only provides monitoring, mapping and ablation, but also provides the ability to perform the ablation at the patient\u2019s bedside. To date, the technology has demonstrated seizure reduction or seizure freedom for most patients that have received an ablation with the OneRF System.<\/p>\n

\u201cThis milestone further validates the intended benefits of our OneRF\u00ae<\/sup> platform,\u201d said Dave Rosa, CEO of NeuroOne. \u201cOur next step is to leverage the technology for other applications, including our OneRF\u00ae<\/sup> Trigeminal Nerve Ablation System to treat facial pain, for which we filed a 510(k) submission<\/a> to the FDA in April 2025.\u201d<\/p>\n

\u201cAround this time last year, I was having multiple seizures every day, which interfered with so many things in my life,\u201d stated Clara. \u201cHowever, since the procedure, I completely stopped having seizures. I\u2019ve started college full time. I\u2019ve gone fishing. I\u2019ve enjoyed peaceful dinners with my family. My life has changed for the better, and I couldn\u2019t be more grateful.\u201d<\/p>\n

Dr. Brin Freund, who has overseen Clara\u2019s epilepsy treatment, stated: \u201cOur interaction with the OneRF\u00ae<\/sup> Ablation System has been positive and shown excellent results for Clara. I believe there is a compelling case for further clinical and research opportunities using this platform to expand treatment capabilities.\u201d<\/p>\n

\n About NeuroOne<\/strong>\n <\/p>\n

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) is developing and commercializing minimally invasive and hi-definition solutions for EEG recording, monitoring, ablation, drug delivery and brain stimulation solutions for patients suffering from epilepsy, Parkinson\u2019s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. The Company may also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. For more information, visit\u00a0nmtc1.com<\/a>.<\/u><\/p>\n

\n Forward Looking Statements<\/strong>\n <\/p>\n

This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this press release may be a forward\u2013looking statement that reflects NeuroOne\u2019s current views about future events and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward\u2013looking statements by the words or phrases \u201cmay,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cforecasts,\u201d \u201cobjective,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cpotential,\u201d \u201ctarget,\u201d \u201cseek,\u201d \u201ccontemplate,\u201d \u201ccontinue, \u201cfocused on,\u201d \u201ccommitted to\u201d and \u201congoing,\u201d or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward\u2013looking statements may include statements regarding our ability to scale our technology across multiple markets, our ability to create partnerships with top-tier strategic partners for other potential applications, including spinal cord stimulation for back pain management and our drug delivery program, and our business strategy, market size, and other potential growth opportunities. Although NeuroOne believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations for the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks related to whether the Company will continue to maintain compliance with all Nasdaq continued listing requirements, risks that our strategic partnerships may not facilitate the commercialization or market acceptance of our technology\u037e whether due to supply chain disruptions, labor shortages or otherwise\u037e risks that our technology will not perform as expected based on results of our pre-clinical and clinical trials\u037e risks related to uncertainties associated with the Company\u2019s capital requirements to achieve its business objectives and ability to raise additional funds: the risk that we may not be able to secure or retain coverage or adequate reimbursement for our technology\u037e uncertainties inherent in the development process of our technology\u037e risks related to changes in regulatory requirements or decisions of regulatory authorities\u037e that we may not have accurately estimated the size and growth potential of the markets for our technology\u037e risks relate to clinical trial patient enrollment and the results of clinical trials\u037e that we may be unable to protect our intellectual property rights\u037e and other risks, uncertainties and assumptions, including those described under the heading \u201cRisk Factors\u201d in our filings with the Securities and Exchange Commission. These forward\u2013looking statements speak only as of the date of this press release and NeuroOne undertakes no obligation to revise or update any forward\u2013looking statements for any reason, even if new information becomes available in the future.<\/p>\n

Caution: Federal law restricts this device to sale by or on the order of a physician.<\/p>\n

Disclaimer: This recounts one patient\u2019s experience and may not be representative of all patient outcomes.<\/p>\n

\n IR Contact<\/strong>
\n
MZ Group \u2013 MZ North America
NMTC@mzgroup.us<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Patient Treated with OneRF \u00ae Ablation System Previously Experienced up to 10 Seizures a Day EDEN PRAIRIE, Minn., June 23, 2025 (GLOBE NEWSWIRE) — NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced that Clara\u2014an early patient treated with the Company\u2019s patented OneRF\u00ae Ablation System\u2014has successfully surpassed the one year milestone of being seizure free. Clara was one of the first patients to undergo treatment using NeuroOne\u2019s OneRF\u00ae platform. Since the procedure in June 2024, Clara has been completely seizure-free, which has greatly improved her quality of life. Videos of Clara\u2019s journey can be found on the company\u2019s website, as … <\/p>\n

Continue reading “NeuroOne\u00ae Patient Surpasses One Year Milestone of Seizure Freedom Following Treatment with OneRF\u00ae Ablation System”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-862646","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nNeuroOne\u00ae Patient Surpasses One Year Milestone of Seizure Freedom Following Treatment with OneRF\u00ae Ablation System - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/neuroone-patient-surpasses-one-year-milestone-of-seizure-freedom-following-treatment-with-onerf-ablation-system\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NeuroOne\u00ae Patient Surpasses One Year Milestone of Seizure Freedom Following Treatment with OneRF\u00ae Ablation System - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Patient Treated with OneRF \u00ae Ablation System Previously Experienced up to 10 Seizures a Day EDEN PRAIRIE, Minn., June 23, 2025 (GLOBE NEWSWIRE) — NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced that Clara\u2014an early patient treated with the Company\u2019s patented OneRF\u00ae Ablation System\u2014has successfully surpassed the one year milestone of being seizure free. Clara was one of the first patients to undergo treatment using NeuroOne\u2019s OneRF\u00ae platform. Since the procedure in June 2024, Clara has been completely seizure-free, which has greatly improved her quality of life. Videos of Clara\u2019s journey can be found on the company\u2019s website, as … Continue reading "NeuroOne\u00ae Patient Surpasses One Year Milestone of Seizure Freedom Following Treatment with OneRF\u00ae Ablation System"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/neuroone-patient-surpasses-one-year-milestone-of-seizure-freedom-following-treatment-with-onerf-ablation-system\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-23T14:17:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ3MjE1NiM3MDAxNTE5IzUwMDExNDgzNA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuroone-patient-surpasses-one-year-milestone-of-seizure-freedom-following-treatment-with-onerf-ablation-system\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuroone-patient-surpasses-one-year-milestone-of-seizure-freedom-following-treatment-with-onerf-ablation-system\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"NeuroOne\u00ae Patient Surpasses One Year Milestone of Seizure Freedom Following Treatment with OneRF\u00ae Ablation System\",\"datePublished\":\"2025-06-23T14:17:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuroone-patient-surpasses-one-year-milestone-of-seizure-freedom-following-treatment-with-onerf-ablation-system\\\/\"},\"wordCount\":1010,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuroone-patient-surpasses-one-year-milestone-of-seizure-freedom-following-treatment-with-onerf-ablation-system\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ3MjE1NiM3MDAxNTE5IzUwMDExNDgzNA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuroone-patient-surpasses-one-year-milestone-of-seizure-freedom-following-treatment-with-onerf-ablation-system\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuroone-patient-surpasses-one-year-milestone-of-seizure-freedom-following-treatment-with-onerf-ablation-system\\\/\",\"name\":\"NeuroOne\u00ae Patient Surpasses One Year Milestone of Seizure Freedom Following Treatment with OneRF\u00ae Ablation System - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuroone-patient-surpasses-one-year-milestone-of-seizure-freedom-following-treatment-with-onerf-ablation-system\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuroone-patient-surpasses-one-year-milestone-of-seizure-freedom-following-treatment-with-onerf-ablation-system\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ3MjE1NiM3MDAxNTE5IzUwMDExNDgzNA==\",\"datePublished\":\"2025-06-23T14:17:35+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuroone-patient-surpasses-one-year-milestone-of-seizure-freedom-following-treatment-with-onerf-ablation-system\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuroone-patient-surpasses-one-year-milestone-of-seizure-freedom-following-treatment-with-onerf-ablation-system\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuroone-patient-surpasses-one-year-milestone-of-seizure-freedom-following-treatment-with-onerf-ablation-system\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ3MjE1NiM3MDAxNTE5IzUwMDExNDgzNA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ3MjE1NiM3MDAxNTE5IzUwMDExNDgzNA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuroone-patient-surpasses-one-year-milestone-of-seizure-freedom-following-treatment-with-onerf-ablation-system\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NeuroOne\u00ae Patient Surpasses One Year Milestone of Seizure Freedom Following Treatment with OneRF\u00ae Ablation System\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NeuroOne\u00ae Patient Surpasses One Year Milestone of Seizure Freedom Following Treatment with OneRF\u00ae Ablation System - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/neuroone-patient-surpasses-one-year-milestone-of-seizure-freedom-following-treatment-with-onerf-ablation-system\/","og_locale":"en_US","og_type":"article","og_title":"NeuroOne\u00ae Patient Surpasses One Year Milestone of Seizure Freedom Following Treatment with OneRF\u00ae Ablation System - Market Newsdesk","og_description":"Patient Treated with OneRF \u00ae Ablation System Previously Experienced up to 10 Seizures a Day EDEN PRAIRIE, Minn., June 23, 2025 (GLOBE NEWSWIRE) — NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced that Clara\u2014an early patient treated with the Company\u2019s patented OneRF\u00ae Ablation System\u2014has successfully surpassed the one year milestone of being seizure free. Clara was one of the first patients to undergo treatment using NeuroOne\u2019s OneRF\u00ae platform. Since the procedure in June 2024, Clara has been completely seizure-free, which has greatly improved her quality of life. Videos of Clara\u2019s journey can be found on the company\u2019s website, as … Continue reading \"NeuroOne\u00ae Patient Surpasses One Year Milestone of Seizure Freedom Following Treatment with OneRF\u00ae Ablation System\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/neuroone-patient-surpasses-one-year-milestone-of-seizure-freedom-following-treatment-with-onerf-ablation-system\/","og_site_name":"Market Newsdesk","article_published_time":"2025-06-23T14:17:35+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ3MjE1NiM3MDAxNTE5IzUwMDExNDgzNA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuroone-patient-surpasses-one-year-milestone-of-seizure-freedom-following-treatment-with-onerf-ablation-system\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuroone-patient-surpasses-one-year-milestone-of-seizure-freedom-following-treatment-with-onerf-ablation-system\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"NeuroOne\u00ae Patient Surpasses One Year Milestone of Seizure Freedom Following Treatment with OneRF\u00ae Ablation System","datePublished":"2025-06-23T14:17:35+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuroone-patient-surpasses-one-year-milestone-of-seizure-freedom-following-treatment-with-onerf-ablation-system\/"},"wordCount":1010,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuroone-patient-surpasses-one-year-milestone-of-seizure-freedom-following-treatment-with-onerf-ablation-system\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ3MjE1NiM3MDAxNTE5IzUwMDExNDgzNA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuroone-patient-surpasses-one-year-milestone-of-seizure-freedom-following-treatment-with-onerf-ablation-system\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/neuroone-patient-surpasses-one-year-milestone-of-seizure-freedom-following-treatment-with-onerf-ablation-system\/","name":"NeuroOne\u00ae Patient Surpasses One Year Milestone of Seizure Freedom Following Treatment with OneRF\u00ae Ablation System - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuroone-patient-surpasses-one-year-milestone-of-seizure-freedom-following-treatment-with-onerf-ablation-system\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuroone-patient-surpasses-one-year-milestone-of-seizure-freedom-following-treatment-with-onerf-ablation-system\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ3MjE1NiM3MDAxNTE5IzUwMDExNDgzNA==","datePublished":"2025-06-23T14:17:35+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuroone-patient-surpasses-one-year-milestone-of-seizure-freedom-following-treatment-with-onerf-ablation-system\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/neuroone-patient-surpasses-one-year-milestone-of-seizure-freedom-following-treatment-with-onerf-ablation-system\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuroone-patient-surpasses-one-year-milestone-of-seizure-freedom-following-treatment-with-onerf-ablation-system\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ3MjE1NiM3MDAxNTE5IzUwMDExNDgzNA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ3MjE1NiM3MDAxNTE5IzUwMDExNDgzNA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuroone-patient-surpasses-one-year-milestone-of-seizure-freedom-following-treatment-with-onerf-ablation-system\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"NeuroOne\u00ae Patient Surpasses One Year Milestone of Seizure Freedom Following Treatment with OneRF\u00ae Ablation System"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/862646","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=862646"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/862646\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=862646"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=862646"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=862646"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}